no metadatahttps://benchmarkantibodies.com/product/rabbit-anti-pr-monoclonal-antibody-zr4-6434/
Skip to content

rabbit anti-PR monoclonal antibody (ZR4) 6434

$160.00$528.00

Antibody summary

  • Rabbit monoclonal to PR
  • Suitable for: Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
  • Reacts with: Human
  • Isotype:IgG
  • Control: Breast carcinomas
  • Visualization: Nuclear
  • 0.1, 0.5, 1.0 mL concentrated, 7 mL prediluted
SKU: 6434parent Category: Tags: , , ,
Weight1 lbs
Dimensions9 × 5 × 2 in
host

mouse

isotype

IgG

clonality

monoclonal

concentration

concentrate, predilute

applications

IHC

reactivity

human

available size

0.1 mL, 0.5 mL, 1 mL concentrated, 7 mL prediluted

rabbit anti-PR monoclonal antibody ZR4 6434

antibody
Database link:
human P06401
Tested applications
IHC
Recommended dilutions
Concentrated 1:200-400
Applicaiton Notes
Breast carcinomas
Immunogen
Recombinant fragment (around aa 1-200) of human PGR (exact sequence is proprietary)
Size and concentration
7 mL prediluted or 0.1, 0.5, 1.0 mL and concentrated
Form
liquid
Storage Instructions
2-8°C for short term, for longer term at -20°C. Avoid freeze / thaw cycles.
Purity
affinity purified
Clonality
monoclonal
Isotype
IgG
Compatible secondaries
goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512
goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079
goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863
goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371
goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715
goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720
Isotype control
Rabbit polyclonal - Isotype Control
target relevance
Protein names
Progesterone receptor (PR) (Nuclear receptor subfamily 3 group C member 3)
Protein family
Nuclear hormone receptor family, NR3 subfamily
Mass
98981Da
Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Depending on the isoform, progesterone receptor functions as a transcriptional activator or repressor. {ECO:0000269|PubMed:10757795, ECO:0000269|PubMed:1587864, ECO:0000269|PubMed:37478846, ECO:0000269|PubMed:9407067, ECO:0000305}.; [Isoform A]: Ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity including repression of its isoform B, MR and ER. Transrepressional activity may involve recruitment of corepressor NCOR2. {ECO:0000269|PubMed:7969170, ECO:0000269|PubMed:8180103, ECO:0000269|PubMed:8264658, ECO:0000305, ECO:0000305|PubMed:10757795}.; [Isoform B]: Transcriptional activator of several progesteron-dependent promoters in a variety of cell types. Involved in activation of SRC-dependent MAPK signaling on hormone stimulation. {ECO:0000269|PubMed:7969170}.; [Isoform 4]: Increases mitochondrial membrane potential and cellular respiration upon stimulation by progesterone.
Subellular location
Nucleus. Cytoplasm. Note=Nucleoplasmic shuttling is both hormone- and cell cycle-dependent. On hormone stimulation, retained in the cytoplasm in the G(1) and G(2)/M phases.; [Isoform A]: Nucleus. Cytoplasm. Note=Mainly nuclear.; [Isoform 4]: Mitochondrion outer membrane {ECO:0000269|PubMed:23518922}.
Tissues
In reproductive tissues the expression of isoform A and isoform B varies as a consequence of developmental and hormonal status. Isoform A and isoform B are expressed in comparable levels in uterine glandular epithelium during the proliferative phase of the menstrual cycle. Expression of isoform B but not of isoform A persists in the glands during mid-secretory phase. In the stroma, isoform A is the predominant form throughout the cycle. Heterogeneous isoform expression between the glands of the endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli. {ECO:0000269|PubMed:11041221}.
Structure
Interacts with SMARD1 and UNC45A. Interacts with CUEDC2; the interaction promotes ubiquitination, decreases sumoylation, and represses transcriptional activity. Interacts with PIAS3; the interaction promotes sumoylation of PR in a hormone-dependent manner, inhibits DNA-binding, and alters nuclear export. Interacts with SP1; the interaction requires ligand-induced phosphorylation on Ser-345 by ERK1/2 MAPK. Interacts with PRMT2. Isoform A interacts with NCOR2. Isoform B (but not isoform A) interacts with NCOA2 and NCOA1. Isoform B (but not isoform A) interacts with KLF9. Interacts with GTF2B (PubMed:1517211). {ECO:0000250|UniProtKB:Q00175, ECO:0000269|PubMed:10757795, ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:1517211, ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:18202149}.
Post-translational modification
Phosphorylated on multiple serine sites. Several of these sites are hormone-dependent. Phosphorylation on Ser-294 occurs preferentially on isoform B, is highly hormone-dependent and modulates ubiquitination and sumoylation on Lys-388. Phosphorylation on Ser-102 and Ser-345 also requires induction by hormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 and Ser-400 is increased in response to progesterone and can be phosphorylated in vitro by the CDK2-A1 complex. Increased levels of phosphorylation on Ser-400 also in the presence of EGF, heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2 is ligand-independent, and increases nuclear translocation and transcriptional activity. Phosphorylation at Ser-162 and Ser-294, but not at Ser-190, is impaired during the G(2)/M phase of the cell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is required for interaction with SP1. {ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:11110801, ECO:0000269|PubMed:15572662, ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:7476977, ECO:0000269|PubMed:8702648, ECO:0000269|PubMed:9171245}.; Sumoylation is hormone-dependent and represses transcriptional activity. Sumoylation on all three sites is enhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388, the main site of sumoylation, is repressed by ubiquitination on the same site, and modulated by phosphorylation at Ser-294. {ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:8702648}.; Ubiquitination is hormone-dependent and represses sumoylation on the same site (PubMed:10628747, PubMed:10655479, PubMed:15798179, PubMed:17173941, PubMed:17717077, PubMed:18202149, PubMed:8702648). Promoted by MAPK-mediated phosphorylation on Ser-294 (PubMed:10628747, PubMed:10655479, PubMed:15798179, PubMed:17173941, PubMed:17717077, PubMed:18202149, PubMed:8702648). Ubiquitinated by UBR5, leading to its degradation: UBR5 specifically recognizes and binds ligand-bound PGR when it is not associated with coactivators (NCOAs) (PubMed:37478846). In presence of NCOAs, the UBR5-degron is not accessible, preventing its ubiquitination and degradation (PubMed:37478846). {ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:37478846, ECO:0000269|PubMed:8702648}.; Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation. {ECO:0000269|PubMed:22031296}.
Domain
Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-term
Target Relevance information above includes information from UniProt accession: P06401
The UniProt Consortium

Data

Human breast carcinoma stained with anti-PR antibody using peroxidase-conjugate and DAB chromogen. Note the nuclear staining of tumor cells.
Human breast carcinoma stained with anti-PR antibody using peroxidase-conjugate and DAB chromogen. Note the nuclear staining of tumor cells.

Publications

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.




pmidtitleauthorscitation

Protocols

relevant to this product
IHC

Documents

#
Please enter your product and batch number here to retrieve - product datasheet, SDS, and QC information.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.